We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Avelas Biosciences announced the first patient has been dosed in Period 2 of its Phase 2 clinical trial of AVB-620 in women with primary, nonrecurrent breast cancer undergoing surgery.